Disease & disorder

cholangiocarcinoma

MONDO:0019087

A carcinoma that arises from the intrahepatic biliary tree (intrahepatic cholangiocarcinoma) or from the junction, or adjacent to the junction, of the right and left hepatic ducts (hilar cholangiocarcinoma). Grossly, the malignant lesions are solid, nodular, and grayish. Morphologically, the vast majority of cases are adenocarcinomas. Signs and symptoms include malaise, weight loss, right upper quadrant abdominal pain, and night sweats. Early detection is difficult and the prognosis is generally poor.

Clinical trials79
Recruiting15
Drug concepts studied20
Synonyms5

Research intelligence

Directly mapped studies only · unique clinical trials

Current registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.

Medications under investigation

Verified disease and drug mappings that co-occur within the same study; not evidence of effectiveness.

Loading mapped interventions…

MONDO disease family

Loading verified ontology relationships…

Recruiting studies by city

Loading research-site locations…

Trial status

Loading…

Trial phase

Loading…

Study start year

Loading…

Investigated drug interventions

Loading…

Clinical trials

40 shown
TCR1188-ABC Cells in KRAS-mutated CancersNCT07594067 · 2026-08-01
RECRUITING
Evaluation of Skin Tests in Biotherapy AllergiesNCT06971848 · 2026-06-17
RECRUITING
18F-T2 PET/CT Imaging for CAIX Positive Solid TumorsNCT07557225 · 2026-04-27
RECRUITING
Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma (POELH-III)NCT07161869 · 2026-02-05
RECRUITING
Laryngopharyngeal Injury After Endotracheal Intubation Under General AnesthesiaNCT07359586 · 2025-11-01
RECRUITING
A Study of LY4337713 in Participants With FAP-Positive Solid TumorsNCT07213791 · 2025-10-22
RECRUITING
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer DetectionNCT06503146 · 2025-09-09
RECRUITING
A Study of GV20-0251 in Advanced or Refractory Solid TumorsNCT07106827 · 2025-09-04
RECRUITING
A Study of PHST001 in Advanced Solid TumorsNCT06840886 · 2025-03-31
RECRUITING
Trop2-targeted immunoPET Imaging of Solid TumorsNCT06851663 · 2024-12-23
RECRUITING
Agnostic Therapy in Rare Solid TumorsNCT06638931 · 2024-07-16
RECRUITING
Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast CancerNCT06199895 · 2023-11-28
RECRUITING
Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes(CAR-T) for CEA Positive Advanced Malignant Solid TumorsNCT06126406 · 2023-11-06
RECRUITING
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical CarcinomaNCT05286814 · 2022-10-24
RECRUITING
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryNCT03452774 · 2018-01-01
RECRUITING
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.NCT07623642 · 2026-06-02
NOT_YET_RECRUITING
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic CancersNCT07118176 · 2025-08-01
ACTIVE_NOT_RECRUITING
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid TumorsNCT06777316 · 2025-01-22
ACTIVE_NOT_RECRUITING
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to DrugsNCT04985357 · 2024-11-01
WITHDRAWN
INSPIRE: a Multi-Cancer Early Detection StudyNCT06440018 · 2024-07-20
UNKNOWN
A Study to Investigate APL-5125 in Adults With Advanced Solid TumorsNCT06399757 · 2024-06-18
COMPLETED
Plasma Metabolic Biomarkers for Multi-Cancer DiagnosisNCT06363123 · 2024-03-29
UNKNOWN
Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90)NCT05872867 · 2024-03-14
UNKNOWN
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid TumorsNCT06010862 · 2023-09-30
UNKNOWN
89Zr-girentuximab for PET Imaging of CAIX Positive Solid TumorsNCT05563272 · 2023-06-06
TERMINATED
A Study of CDX-585 in Patients With Advanced MalignanciesNCT05788484 · 2023-05-11
COMPLETED
Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRsNCT05292859 · 2023-03-01
COMPLETED
Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal CarcinomatosisNCT05185947 · 2022-10-13
COMPLETED
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)NCT05461430 · 2022-07-15
COMPLETED
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing CancerNCT05451849 · 2022-06-21
TERMINATED
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid TumorsNCT05311618 · 2022-05-11
UNKNOWN
To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid TumorsNCT05253053 · 2022-04-13
COMPLETED
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid TumorsNCT05194735 · 2022-04-04
TERMINATED
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid TumorsNCT05215574 · 2022-03-31
ACTIVE_NOT_RECRUITING
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid TumorsNCT05194072 · 2022-01-12
TERMINATED
Milademetan in Advanced/Metastatic Solid TumorsNCT05012397 · 2021-11-01
TERMINATED
A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid TumorsNCT04853017 · 2021-10-04
COMPLETED
HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid TumorsNCT05124743 · 2021-09-24
TERMINATED
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)NCT05007106 · 2021-09-16
COMPLETED
A Phase I Study of WM-S1-030 in Patients With Advanced Solid TumorsNCT04801095 · 2021-07-14
UNKNOWN

Disease identity and terminology: MONDO. Trial relationships: ClinicalTrials.gov.